Stay updated on Phase 3 Daclatasvir/Asunaprevir in Hepatitis C Clinical Trial

Sign up to get notified when there's something new on the Phase 3 Daclatasvir/Asunaprevir in Hepatitis C Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Phase 3 Daclatasvir/Asunaprevir in Hepatitis C Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:34:36.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study completion date for the Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection.
    Difference
    0.1%
    Check dated 2024-06-06T14:38:30.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for clinical trial participants, specifying requirements such as health conditions and prior treatments. The new information also provides a link for more details on BMS clinical trial participation.
    Difference
    17%
    Check dated 2024-05-22T21:37:03.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:31:11.000Z thumbnail image

Stay in the know with updates to Phase 3 Daclatasvir/Asunaprevir in Hepatitis C Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Phase 3 Daclatasvir/Asunaprevir in Hepatitis C Clinical Trial page.